share_log

Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32

Benzinga ·  Apr 3, 2023 13:32

Aegis Capital analyst David Bouchey initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $32.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment